DOI 10.1111/j.1464-410x.2007.06926.x
The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
Аннотация
OBJECTIVE
To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).
PATIENTS AND
METHODS
We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (> or =8 voids/24 h) and UUI (> or=5 episodes/week) for > or = 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.
RESULTS
Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.
CONCLUSIONS
These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.